NCT06853197

Bioavailability of Seven Mitopure Formulations

A Comparative Pharmacokinetic Profiles of Urolithin A Formulations in Healthy Volunteers: a Randomized, Open-label, Single-dose, Parallel-arm Study

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 84 (actual)
• Sponsor: Amazentis SA · Industry
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

This study's design as an open-label, single-period, single-dose, randomized trial that aligns with the objective of characterizing the concentration-time profiles of seven Urolithin A (Mitopure) formulations in a controlled setting. The inclusion criteria, stringent fasting requirements, standardized fluid intake and strict dietary restriction protocols ensure homogeneity among the study participants, enhancing the reliability of the outcomes. Ultimately, this clinical trial aims to contribute valuable insights into the pharmacokinetic behavior of the different Urolithin A formulations, facilitating informed decisions for future developments and applications in the realm of health and wellness.

Conditions

• Healthy Adults

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Mitopure (Urolithin A)	Mitopure (Urolithin A) is gut microbiome derived postbiotic that has been shown to improve muscle and mitochondrial health

Timeline

• Start date: 2025-03-17
• Primary completion: 2025-05-05
• Completion: 2025-05-05
• First posted: 2025-02-28
• Last updated: 2025-05-21

Locations

1 site across 1 country: India